industry news

Men with metastatic castration-resistant prostate cancer (mCRPC) may have a new course of treatment available to them.

The Food and Drug Administration (FDA) has approved a new formulation of Yonsa (abiraterone acetate) in combination with methylprednisone. The approval comes as a result of a study showing equal therapeutic effects to Zytiga (another abiraterone acetate treatment), with fewer adverse effects.

You can read more via this Cure Today article.